We came across a bullish thesis on uniQure N.V. on Truffle Pigs’s Substack. In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.'s share was trading at $63.65 as of October 9th. QURE’s forward P/E was 27.93 according to Yahoo Finance.
[caption id="attachment_557944" align="aligncenter" width="750"]uniQure’s AMT-130 represents a groundbreaking advancement in Huntington’s disease, providing the first credible evidence that a gene therapy can meaningfully alter the course of this fatal neurodegenerative...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.